Commonwealth Equity Services LLC Has $332,000 Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Commonwealth Equity Services LLC raised its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 25.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,241 shares of the company’s stock after buying an additional 9,058 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Recursion Pharmaceuticals were worth $332,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of RXRX. Mubadala Investment Co PJSC acquired a new stake in Recursion Pharmaceuticals in the fourth quarter worth $128,041,000. ARK Investment Management LLC lifted its holdings in Recursion Pharmaceuticals by 14.5% during the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after acquiring an additional 3,555,357 shares in the last quarter. Norges Bank acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $34,825,000. Baillie Gifford & Co. increased its holdings in shares of Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after acquiring an additional 2,522,132 shares in the last quarter. Finally, Kinnevik AB publ raised its position in shares of Recursion Pharmaceuticals by 14.4% during the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after purchasing an additional 1,500,000 shares during the period. 89.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

RXRX has been the subject of a number of research reports. Needham & Company LLC lowered their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group dropped their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. KeyCorp reduced their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.40.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at approximately $3,860,644.97. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total transaction of $97,070.56. Following the sale, the director now owns 7,155,663 shares in the company, valued at approximately $60,680,022.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares of the company’s stock, valued at $3,860,644.97. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 231,682 shares of company stock worth $1,633,304. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $6.67 on Tuesday. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $15.74. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -4.17 and a beta of 0.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The business has a 50-day moving average of $7.12 and a 200-day moving average of $8.29.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. During the same quarter in the previous year, the firm posted ($0.38) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 30.9% on a year-over-year basis. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.